Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Other Non-Current Liabilities (2021 - 2023)

Historic Other Non-Current Liabilities for Arcturus Therapeutics Holdings (ARCT) over the last 3 years, with Q4 2023 value amounting to $497000.0.

  • Arcturus Therapeutics Holdings' Other Non-Current Liabilities fell 8227.53% to $497000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $497000.0, marking a year-over-year decrease of 8227.53%. This contributed to the annual value of $497000.0 for FY2023, which is 8227.53% down from last year.
  • As of Q4 2023, Arcturus Therapeutics Holdings' Other Non-Current Liabilities stood at $497000.0, which was down 8227.53% from $976000.0 recorded in Q3 2023.
  • In the past 5 years, Arcturus Therapeutics Holdings' Other Non-Current Liabilities ranged from a high of $3.7 million in Q3 2022 and a low of $358000.0 during Q1 2021
  • Its 3-year average for Other Non-Current Liabilities is $1.5 million, with a median of $1.3 million in 2023.
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Other Non-Current Liabilities surged by 16370.16% in 2022 and then tumbled by 8227.53% in 2023.
  • Over the past 3 years, Arcturus Therapeutics Holdings' Other Non-Current Liabilities (Quarter) stood at $1.4 million in 2021, then skyrocketed by 101.15% to $2.8 million in 2022, then tumbled by 82.28% to $497000.0 in 2023.
  • Its Other Non-Current Liabilities stands at $497000.0 for Q4 2023, versus $976000.0 for Q3 2023 and $1.3 million for Q2 2023.